Bicara Therapeutics (BCAX)

• Market cap: $881M
• 1 day: -0.12%
• 5 days: -2.37%
• 1 month: -14.82%
• 3 months: -10.76%
• 6 months: 78.58%
• Year to date: -1.77%
• 1 year: 3.21%
• 5 years: -31.27%
• 10 years: -31.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.